Coherus Biosciences EBIT

Coherus Biosciences (CHRS) currently reports a EBIT of $-160M as of June 2026. That compares with $-140M in the prior-year period — down 14.5% year over year. That is below the Healthcare sector average of $22B. Use the charts on this page to explore Coherus Biosciences's EBIT history and peer comparisons.

Coherus Biosciences's EBIT decreased from $-140M to $-160M — a 14.5% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Coherus Biosciences's EBIT of $-160M is lower than the Healthcare sector average of $22B. That is roughly 100.7% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Coherus Biosciences reported $-160M in EBIT as of June 2026. That compares with $-140M in the prior-year period — down 14.5% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-160M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $22B. From there, open related valuation or income-statement pages for Coherus Biosciences, and consider following CHRS for alerts when major investors trade the stock.